Structure Therapeutics, Inc. (GPCR)
25.51
-0.16
(-0.62%)
USD |
NASDAQ |
Oct 09, 16:00
25.51
0.00 (0.00%)
After-Hours: 17:16
Structure Therapeutics Cash from Operations (Quarterly) : -120.38M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -120.38M |
| March 31, 2026 | 15.28M |
| December 31, 2025 | -64.69M |
| September 30, 2025 | -51.05M |
| June 30, 2025 | -54.75M |
| March 31, 2025 | -52.30M |
| December 31, 2024 | -36.44M |
| September 30, 2024 | -19.87M |
| June 30, 2024 | -26.37M |
| Date | Value |
|---|---|
| March 31, 2024 | -34.02M |
| December 31, 2023 | -21.91M |
| September 30, 2023 | -20.72M |
| June 30, 2023 | -16.61M |
| March 31, 2023 | -20.18M |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | -9.943M |
| March 31, 2022 | -13.46M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Eli Lilly & Co. | 10.69B |
| Novo Nordisk A/S | 8.364B |
| Pfizer Inc. | 835.00M |
| Viking Therapeutics, Inc. | -125.17M |
| Liquidia Corp. | 80.24M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 75.10M |
| Cash from Financing (Quarterly) | 2.091M |
| Free Cash Flow | -225.05M |
| Free Cash Flow Per Share (Quarterly) | -1.656 |
| Free Cash Flow to Equity (Quarterly) | -120.77M |
| Free Cash Flow to Firm (Quarterly) | -120.34M |
| Free Cash Flow Yield | -13.43% |